Ascletis Receives US$20M Investment from Goldman Sachs
Summary
Ascletis, a China-based biotechnology company focused on innovative drug development, received a US$20m investment from Goldman Sachs.So far, Ascletis has completed two rounds of financing within the past two months.The company intends to use the funds to to strengthen R&D capacity, and broaden the scope of its R&D pipeline.Led by Jinzi Wu, PhD., founder, President and CEO, Ascletis is a biotechnology company dedicated to discovering, developing and commercializing new treatments for infectious diseases and cancer.To date, the company owns four products that are in the clinical phase with proprietary intellectual property rights.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected